AUROPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.0
| Stock Code | AUROPHARMA | Market Cap | 86,788 Cr. | Current Price | 1,494 ₹ | High / Low | 1,550 ₹ |
| Stock P/E | 35.7 | Book Value | 391 ₹ | Dividend Yield | 0.27 % | ROCE | 13.0 % |
| ROE | 11.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,421 ₹ | DMA 200 | 1,289 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 692 Cr. | PAT Prev Qtr | 595 Cr. |
| RSI | 59.9 | MACD | 1.68 | Volume | 26,28,140 | Avg Vol 1Wk | 18,15,118 |
| Low price | 1,016 ₹ | High price | 1,550 ₹ | PEG Ratio | 1.38 | Debt to equity | 0.19 |
| 52w Index | 89.4 % | Qtr Profit Var | 69.6 % | EPS | 41.6 ₹ | Industry PE | 32.5 |
📊 Analysis: Aurobindo Pharma (AUROPHARMA) demonstrates solid fundamentals with ROE at 11.2% and ROCE at 13.0%, supported by a manageable debt-to-equity ratio of 0.19. The company has delivered strong quarterly PAT growth (₹692 Cr vs ₹595 Cr), reflecting operational efficiency. Valuation-wise, the stock trades at a P/E of 35.7, slightly above the industry average of 32.5, but the PEG ratio of 1.38 indicates a reasonable balance between price and growth. Dividend yield is modest at 0.27%. Technical indicators (RSI 59.9, MACD 1.68) suggest bullish momentum, with the stock trading near its 52-week high.
💰 Entry Price Zone: Ideal accumulation range lies between ₹1,300 – ₹1,400, closer to its 50 DMA support, offering better valuation comfort.
📈 Exit / Holding Strategy: Long-term investors can hold for 3–5 years given strong growth metrics and improving profitability. Exit strategy should be considered if price approaches ₹1,550 resistance without earnings catch-up. Fresh entries should wait for correction towards the lower band.
🔵 Positive
- Strong quarterly PAT growth of 69.6% (₹692 Cr vs ₹595 Cr).
- Reasonable [PEG ratio](ca://s?q=Explain_PEG_ratio) of 1.38, showing fair growth-to-price alignment.
- Healthy [EPS](ca://s?q=Explain_EPS) of ₹41.6.
- Increased [FII](ca://s?q=What_is_FII) holdings (+1.29%) showing foreign confidence.
🟠 Limitation
- Moderate [ROE](ca://s?q=Explain_ROE) of 11.2% and [ROCE](ca://s?q=Explain_ROCE) of 13.0%.
- [P/E ratio](ca://s?q=Explain_PE_ratio) of 35.7 slightly above industry average of 32.5.
- Low [dividend yield](ca://s?q=Dividend_yield_explained) at 0.27%.
- [DII](ca://s?q=What_is_DII) holdings decreased (-1.84%), showing reduced domestic interest.
🔴 Company Negative News
- Valuation slightly above industry average, limiting upside potential.
- Stock trading near 52-week high, reducing margin of safety for new investors.
🟢 Company Positive News
- Strong quarterly PAT growth highlights operational efficiency.
- Positive technical momentum with RSI near 60 and MACD in bullish territory.
🏭 Industry
- Industry P/E at 32.5 highlights peers trading at slightly lower valuations.
- Pharmaceutical sector remains resilient with consistent demand drivers.
📌 Conclusion
AUROPHARMA is fundamentally strong with improving profitability and reasonable growth metrics. Long-term holders can continue, while new investors should wait for correction towards ₹1,300–₹1,400. Exit near ₹1,550 if valuations remain stretched without earnings growth.